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Quantitative proteomics 
analysis of Angiostrongylus 
vasorum‑induced alterations 
in dog serum sheds light 
on the pathogenesis of canine 
angiostrongylosis
Lucienne Tritten1*, Nina Gillis‑Germitsch1,2, Tobias Kockmann3 & Manuela Schnyder1*
Blood contains hundreds of proteins, reflecting ongoing cellular processes and immune reactions. 
Infections with the blood‑dwelling cardiopulmonary nematode Angiostrongylus vasorum in dogs 
manifest with a broad spectrum of clinical signs including respiratory distress, bleeding diathesis and 
neurological signs, and are associated with a perturbed blood protein profile in dogs. However, current 
knowledge does not completely explain the observed pathologies induced by A. vasorum infections, 
including bleeding disorders. Using sera from experimentally infected dogs, dog serum proteome 
was analysed by quantitative mass spectrometry methods over several time points before and after 
inoculation. Following computational analysis, we identified 139 up‑ and downregulated proteins 
after infection (log2 ratio cut‑off ≥ 1.0; q‑value ≤ 0.05). Among upregulated proteins were chitinase 
3‑like 1 and pulmonary surfactant‑associated protein B (log2 fold‑changes ≥ 5). Pathway enrichment 
revealed the complement (especially the lectin pathway) and coagulation cascades as significantly 
affected upon analysis of downregulated proteins. Among them were mannan‑binding lectin 
serine peptidases, ficolin, and coagulation factor XIII‑B. These results bring new elements towards 
understanding the underlying pathomechanisms of bleeding diatheses observed in some A. vasorum-
infected dogs.
Angiostrongylus vasorum is a metastrongylid cardiopulmonary nematode parasite of dogs and wild carnivores 
such as red foxes, causing a range of clinical signs with potentially fatal outcomes in dogs. After ingestion of 
infected gastropods acting as intermediate hosts and a 6 weeks prepatent period, adult worms reside in the 
pulmonary arteries and the right side of the heart of their definitive  hosts1–3. There, they release numerous eggs. 
Hatched first stage larvae migrate through the lungs, inducing verminous pneumonia. If left untreated, the 
infection is associated with a high fatality rate in dogs. Respiratory disease, bleeding disorders, and other diverse 
and unspecific signs may result from an infection with A. vasorum4,5. Dogs showing coagulation deficiency are 
more prone to die as a result of the  infection6–8. The heterogeneous clinical picture of canine angiostrongylosis 
hampers efficient diagnosis as well as timely and appropriate treatment. The pathogenesis of the diverse array 
of clinical signs and especially coagulopathies associated with the infection remain poorly understood. Hypo-
coagulability is more frequently observed than  hypercoagulability6,9 and approximately 20–30% of cases were 
estimated to present with bleeding tendencies or neurological signs induced by  bleeding4,10. Multiple hypotheses 
have been formulated to explain the onset of coagulation disorders; the issue remains nonetheless unresolved 
to date. Antigenic stimulation causing chronic disseminated intravascular coagulation (DIC), acquired deficits 
in von Willebrand and other coagulation factors, (immune-mediated) thrombocytopenia (however, usually 
transient)11–14,  thrombocytopathy7, immune complex-mediated stimulation of coagulation, and the secretion 
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of anticoagulants by the parasite have been  proposed6,11–16. Up to 43% of infected dogs (with and without visible 
clinical signs of bleeding) showed  hyperfibrinolysis7.
Analysing the blood proteome may reveal valuable information: it contains hundreds of proteins, reflect-
ing dynamically ongoing cellular processes and immune reactions. In addition, A. vasorum resides in blood, 
and blood-dwelling parasites are known to modify their hosts’ haemostatic  system17. Several studies reported 
a perturbed protein profile in A. vasorum-infected dogs. Some described high levels of total protein, especially 
of the globulin  fraction18,19. Others noted a transient increase in α1- or α2-globulins and β-globulin fractions in 
infected  dogs15,20. One study reported β-globulins to decrease on day 20 post-infection with A. vasorum before a 
significant increase by day 45, compared to control  animals20. However, these reports do not provide a thorough 
and systematic analysis of all protein fractions.
The analysis of a dysregulated serum protein profile may therefore guide us towards a better understanding 
of the molecular biology behind pathogenesis and be useful in the quest for diagnostic and prognostic bio-
markers. A mass-spectrometric approach enables the deep analysis of the dynamics and specificity of a tissue’s 
proteome in response to a health condition and may point at molecular events compromising the maintenance 
of homeostasis (e.g.21–23).
This report represents a first in-depth analysis of the dynamics of the dog serum proteome over three to five 
time points over the course of an experimental infection with A. vasorum. Our study suggests that the comple-
ment system, the lectin pathway in particular, as well as the innate immune system are negatively impacted by 
the infection progressing to a chronic phase. In addition, coagulation factor XIII, subunit B, involved in the 
stabilization of fibrin clots, appeared to be depleted. These novel insights warrant further targeted investigations, 
since they provide leads towards an explanation for the development of A. vasorum-driven coagulopathies.
Results
Serum from eight dogs was sampled at three time points: (i) before infection, (ii) during pre-patency, and (iii) 
one to three time points after patency (Fig. 1a), subjected to reduction of the protein dynamic concentration 
range by applying combinatorial peptide ligand libraries, and screened for differential abundant proteins by data 
independent acquisition (DIA) executed on a liquid chromatography coupled to mass spectrometry (LC–MS) 
system. A list of identified proteins and peptides is provided in Table S1. The number of proteins that was found 
significantly up- or downregulated (adjusted p-value ≤ 0.05) across the different pairwise comparisons ranged 
between 0 and 49 (Table S1).
Serum profile changes from day‑7 to day 75. Several protein expression changes were observed at 
day 34 p.i. already (Fig. 1b): 8 proteins appeared significantly downregulated; 6 were upregulated. Pulmonary 
surfactant-associated protein B (SFTPB; P17129) further accumulated in dog sera and another ten proteins 
appeared newly up-regulated (for a total of 11 up-regulated proteins) at day 75 p.i. compared to day 34, with 
no down-regulated protein (Fig.  1b). Alteration of protein expression appeared most pronounced at day 75 
p.i., compared to before infection (Fig. 1b), where the levels of a total of 34 proteins were increased and 15 
were decreased (listed in Supplementary Table S1). Levels of chitinase 3-like protein (CHI3L1, D3YJ60), SFTPB 
(E2R0C8), and a saposin B-type domain-containing protein (J9NRT8/J9PA27) increased the most, with fold-
changes up to 20 times between days 75 and -7. Comparing the same time points, the greatest fold-changes for 
downregulated proteins were observed for fibrinogen beta chain (FGB; F1PW65) and secreted protein acidic 
and cysteine rich (SPARC; E2RMA3), although just below the p-value cut-off (set at 0.05). Most significantly 
down-regulated, this time according to the adjusted p-values, were mannan binding lectin serine peptidases 1 
and 2 (MASP1 and -2; F1PQ99, F6USM4), and ficolin-1 (FCN1; J9P7F7).
Downregulated proteins over time. Functional protein–protein interactions for downregulated proteins 
at day 34 and at day 75 p.i. compared to day-7, respectively, are depicted in Fig. 2. MASP1, MASP2, and FCN1 
(and LOC608247, a dog orthologue of FCN1) are known interactors. Their levels are consistently decreased at 
both days 34 and 75 p.i. compared to before infection; however, no further decrease was observed from day 34 
to 75. At day 75, two further interaction networks appeared. The first is composed of coagulation factors FXIII-B 
and FV; the latter interacting in turn with a histidine-rich glycoprotein (HRG; F1PZC6) and SPARC.
Figure 1.  Study design and analysis of protein expression across time and individuals. (A) Serum sampling 
schedule and workflow. Blood was drawn at several time points before and after infection with A. vasorum, 
across the prepatent and patent phases. Samples were processed and subjected to LC–MS proteomic analysis 
to identify alterations in protein levels over time; (B) Volcano plots representing pairwise comparisons across 
the first three time points. 1: comparison day 34 to day-7, 2: comparison day 75 to day 34, 3: comparison day 
75 to day-7. Each protein is represented by one dot and labelled with a Uniprot accession. Significant proteins 
are defined by a combination of adjusted p-value ≤ 0.05, and log2 fold-change ≥ 1 (upregulated; red) or ≤ -1 
(downregulated; blue); (C) Profile plots for selected proteins across time. The x-axis represents time points,  log2 
protein intensities are shown in the y-axis. ADAMTS13 ADAM metallopeptidase with thrombospondin type 1 
motif 13 (J9P430), CFP complement factor properdin (E2RH18), FXIII-B coagulation factor XIII, polypeptide B 
(F1Q041), FV coagulation factor V (F1PN98), FCN1 ficolin (collagen/fibrinogen containing lectin) 1 (J9P7F7), 
MASP1 mannan-binding lectin serine peptidase 1 (F1PQ85), MASP2 mannan-binding lectin serine peptidase 
2 (F6USM4), CHI3L1 chitinase-3-like protein 1 precursor (D3YJ60), SFTPB pulmonary surfactant protein B 
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The most common GO terms (resulting from Blast2GO search) associated with downregulated proteins both 
at days 34 and 75 compared to day-7 were “complement activation, lectin pathway” (GO:0001867) and “proteoly-
sis” (GO:0006508). Similarly, the most common molecular functions were “calcium ion binding” (GO:0005509) 
and “serine-type endopeptidase activity” (GO:0004252), at both time points.
STRING analysis of significantly downregulated proteins at day 34 compared to day-7 revealed an overrepre-
sentation of the Reactome pathway “ficolins bind to repetitive carbohydrate structures of the target cell surface” 
(CFA-2855086, FDR = 1.13e−08), due to the presence of MASP1, MASP2, and FCN1. MASP1, MASP2, and F12 
(E2R9D2) have trypsin activities (Pfam domain, FDR = 9.26e−05), and together with cartilage acidic protein 1 
(CRTAC1; F1PTC8), they share an “EGF-like domain” (FDR = 7.06e−06).
At day 75, MASP1, MASP2, and FCN1 contributed to the enrichment of “ficolins bind to repetitive carbohy-
drate structures of the target cell surface” (FDR = 2.26e−07), to “initial triggering of complement” (CFA-166663, 
FDR = 2.26e−07), and “complement cascade” (CFA-166658, FDR = 9.27e−07), together with properdin (E2RH18). 
FV (F1PN98), FXIII-B (F1Q041) and FGB contributed to “common pathway of fibrin clot formation” (CFA-
140875, FDR = 2.03e−06). FV, FGB, SPARC, and HRG are associated with the “platelet degranulation” pathway 
(CFA-114608, FDR = 6.22e−06). FV, FXIII-B, FGB, SPARC, and HRG contributed to “haemostasis” (CFA-109582, 
FDR = 8.54e−05). Sushi domains (MASP1, MASP2, and FXIII-B) and CUB domains (MASP1, MASP2, and 
ADAMTS13 (E2QUY9)) were overrepresented among the dataset as well.
Changes appeared generally consistent across the 8 individual dogs. Several examples are depicted in Fig. 1c.
Upregulated proteins over time. Among the 6 upregulated proteins at day 34 compared to day-7, one 
item (A0A158PB66), was recognized as an A. cantonensis uncharacterized protein.
SFTPB (P17129 in Fig. 1b) displayed a 3.8-fold and an 8.7-fold increase at days 34 and 75 compared to day-7, 
respectively (see Supplementary Fig. S1). A known interactor, napsin A (NAPSA; F1PWW2), was also found to 
be upregulated at this time point. Reactome pathways “scavenging of haem from plasma” (CFA-216880), “cell 
surface interactions at the vascular wall” (CFA-202733) and “haemostasis” (CFA-109582) were found enriched 
(FDR ≤ 0.05) based on the presence of two dog proteins with antigen binding functions (J9NVC6 and J9JHH5; 
not shown). Reactome pathways “innate immune system” (CFA-168249, FDR = 3.09e−08) and “immune system” 
(CFA-168256, FDR = 1.32e−05) were overrepresented among upregulated proteins (13 out of 34 proteins in total) 
at day 75 compared to before infection (Supplementary Fig S1). Several immunoglobulin-like domains as well 
as saposin-like domains were enriched as well (Pfam domains, FDRs ≤ 0.001). CHI3L1, strongly upregulated at 
day 75 (20-fold), interacts with interleukin enhancer binding factor 2 (ILF2; E2R9T6), also upregulated. Six out 
of 34 upregulated proteins resulting from the same time point comparison were described as ‘Ig-like domain-
containing proteins’.
Trends for dysregulated candidates at later time points. For two dogs, sera sampled on days 104 
and 230 p.i. were analysed additionally. Given the lack of sufficient replicates, these two late time points only 
Figure 2.  Functional protein–protein interactions among downregulated proteins. (A) downregulated proteins 
at day 34 compared to day-7, (B) downregulated proteins at day 75 compared to day-7. ADAMTS13 ADAM 
metallopeptidase with thrombospondin type 1 motif 13, ADIPOQ adiponectin precursor, AMY2B amylase α2B, 
APMAP adipocyte plasma membrane associated protein, CFP complement factor properdin, CRTAC1 cartilage 
acidic protein 1, F12 coagulation factor XII, F13B coagulation factor XIII, polypeptide B, F5 coagulation factor 
V, FCN1/LOC608247 ficolin (collagen/fibrinogen containing lectin) 1, FGB fibrinogen β chain, HRG histidine-
rich glycoprotein, MASP1 mannan-binding lectin serine peptidase 1, MASP2 mannan-binding lectin serine 
peptidase 2, SPARC secreted protein acidic, cysteine-rich, TRFC transferrin receptor protein 1.
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serve the purpose of showing trends. All five time points are shown in Fig. 1c for 9 selected candidates that were 
significantly up- or downregulated by day 75. There was no difference in protein expression between days 75 
and 104, or between days 104 and 230 (summarized in Supplementary Table S1). The only difference between 
expression profiles at days 230 and 75 was a reduced expression in thrombospondin 4 (THBS4; F1PSS2) at the 
later time point (not shown). Proteins like SFTPB appeared consistently upregulated at days 104 and 230 p.i. 
compared to day-7, as well as between days 230 and 34. Similarly, CHI3L1 remained present at higher levels at 
the two later time points compared to days-7 and 34. MASP1 and -2, as well as HRG and FCN1 were consistently 
present at lower levels at days 104 and 230 compared to day-7, as was the case at days 34 and 75. THBS4 was 
depleted at day 230 compared to all the three first time points.
Generally, protein abundance (log2 intensities) measured at days 104 and 230, when the infection can be 
called chronic, confirm the trends observed in earlier patent infections (day 75). Although no conclusion can 
Figure 3.  Average protein expression for 4 candidates across time points in PRM assay. Graphs depict log2 
fold-changes of measured protein intensities, standard errors are indicated. (A) comparison day 34/day-7; (B) 
comparison day 75/day-7; (C) comparison day 75/day 34. Three proteins were found to be downregulated 
over the course of the infection in the main study (DIA experiments and analysis in Spectronaut and MSstat): 
MASP-1 and MASP-2 (F1PQ85 and F6USM4), and FXIII-B (F1Q041). The last protein, SFTPB (P17129), was 
upregulated over time in the main study.
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be drawn from only 2 dogs, it seems that the baseline protein levels (from day-7) are not recovered at those later 
time points.
Confirmation of differential protein abundance by targeted mass spectrometry. Due to lacking 
immunoreagents we developed targeted LC–MS assays for relative quantification of SFTPB, FXIII-B, MASP-1, 
and MASP-2 (Table S2). In summary, targeted re-quantification of the above described serum samples indeed in 
PRM (Parallel Reaction Monitoring) assays confirmed the fold-changes estimated by DIA in expression between 
days-7 and 75 (Fig.  3): SFTPB (P17129) Log2 FC = 6.6 ± 2.0 (log2 FC = 5.5 ± 1.3 in the main study), FXIII-B 
(F1Q041) log2 FC = − 1.4 ± 0.5 (log2 FC = − 1.1 ± 0.2 in the main study), MASP-2 (F6USM4) log2 FC = − 1.0 ± 0.2 
(log2 FC = − 1.4 ± 0.1 in the main study), MASP-1 (F1PQ85) log2 FC = − 1.2 ± 0.3 (log2 FC  = − 1.3 ± 0.2 in the 
main study).
Discussion
The rationale behind this study was to gain knowledge about infection-related serum proteomic patterns, which 
in turn may explain the development of coagulation disorders and potential further pathogenic aspects in A. 
vasorum-infected dogs. To our knowledge, this is the first deep proteomic analysis of blood from infected animals 
covering all infection phases. In order to validate the protein level variations across samples and time points, 
we successfully developed PRM assays including synthetic reference peptides, the first of its kind for dog serum 
proteins.
Alterations of the serum protein profile appeared generally consistent across the 8 individual dogs up to day 
75 p.i. and data from two dogs at days 104 and 230 suggest that these alterations tend to persist. We emphasize 
that data from these two later time points have an indicative function, rather than conclusive, due to the number 
of donor individuals available being reduced to only two. Our study dogs did not show visible signs of bleeding 
upon medical checks (unpublished results,  and5,24). Despite the lack of haematological data for the study dogs at 
the examined time points, our experience shows that laboratory A. vasorum infections lead to severe pulmonary 
changes including vascular thrombosis, but only mild haematological changes, without overt signs of bleeding 
over such a short period of  time5,25. If the measured coagulation times were essentially within reference ranges 
throughout the experiments, the activated partial thromboplastin time (aPTT) was significantly higher in dogs 
receiving a higher infective load at days 63 and 70 p.i. A mild to moderate thrombocytopenia was observed in 
patent infections, especially when the worm burden was  high5. Other studies of natural and laboratory infections 
reported further changes at the level of coagulation factor activity and  coagulability6,7. Here, we discuss a few 
elements of particular interest in this context.
Among upregulated proteins, our data reflect the ongoing anti-helminth immune response and the damage 
inflicted to the infected lungs. CHI3L1 is a secretory glycoprotein expressed by different cell types. Chitinase-like 
proteins (CLP) are enzymatically inactive  molecules27. Each mammalian species exhibits a different collection of 
CLP-encoding  genes28. In mice, all CLPs including CHI3L1 are commonly upregulated in the context of T-helper 
2-driven inflammation of the lungs. In the helminth model Nippostrongylus brasiliensis, CLPs were shown to 
exert antiparasitic functions through IL-17-mediated recruitment of neutrophils, a reaction that causes lung 
 damage27. A known interactor of CHI3L1, ILF2, was also found to be upregulated in the current study. Accord-
ing to Reactome, they contribute to the exocytosis of specific granule lumen proteins by neutrophils, and so, 
play roles in phagocytosis and killing extracellular  pathogens29. ILF2 is an essential transcription factor for T 
cell expression of the IL-2 gene.
SFTPB is a highly hydrophobic apoprotein of the family of c-type lectins. Upon the inspiratory stretch of the 
alveolar cell layer, alveolar pneumocytes secrete surfactant-containing lamellar bodies, which are then reorgan-
ized into the highly surface-active tubular myelin and large multilamellar  vesicles30. In human patients with 
acute respiratory distress syndrome (ARDS), plasma levels of surfactant protein B are elevated as a result of tissue 
 insult31. Similarly, the lungs of A. vasorum-infected dogs are constantly injured by hatching first-stage larvae. 
Like other saposin-like proteins (e.g. NK-lysin, granulysin, and amoebapore), SFTPB exhibits antimicrobial 
activity by interacting with lipid components of cell membranes. Human surfactant protein B was shown to 
induce bacterial killing through aggregation and membrane  permeabilization32. Bacterial aggregation caused 
by other surfactant proteins was proposed to enhance phagocytosis and favour complement activation among 
other  roles33. However, the membranolytic activity is not selective for bacteria, as red blood cell lysis also occurs 
in vitro. Because its effects are inhibited by phospholipids, to which it is naturally associated in vivo, the role of 
endogenous surfactant protein B in alveolar host defence may be  restricted32. However, others found that the 
predominant forms of alveolar immunoreactive surfactant protein B, proprotein and processing intermediate, 
are not bound to surfactant lipids, which would facilitate entry into the  circulation31, leaving the possibility for 
host defence properties outside the lungs as well.
Our data indicate that several players of the complement and coagulation pathways are expressed at lower 
levels with the infection progressing to a chronic stage (day 75 p.i.), as compared to before infection. Evolution-
arily related enzymatic cascades contributing to host defence, coagulation and complement cascades are closely 
interwoven with each other and show many interactions. For example, platelets may become activated as a result 
of complement activation, and vice  versa34. Or, complement C5a also increases the expression of tissue factor 
on  leukocytes35.
Reactome pathways “ficolins bind to repetitive carbohydrate structures of the target cell surface”, “initial 
triggering of complement”, “complement cascade”, “common pathway of fibrin clot formation, and “haemosta-
sis” were overrepresented in our list of downregulated candidates. The complement system plays a crucial role 
in the innate defence against a wide array of pathogens, including  helminths36. Its activation leads to a series 
of proteolytic events that ultimately result in opsonisation and lysis of the pathogen, as well as the generation 
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of inflammation. The complement system is nowadays also regarded as an important link between the innate 
and adaptive immune responses. It can be activated by three different routes: the classical, lectin, or alternative 
 pathways37. The lectin pathway occupies a particular place at an important crossroad between complement and 
coagulation. It gets activated by microbial sugars and relies on pattern recognition receptors (PRRs; in the form 
of e.g., mannose-binding lectins or ficolins, which recognize pathogen-associated molecular patterns (PAMPs)). 
PRRs form complexes with MASP1/MASP2. Binding of PRRs on a pathogen’s surface leads to the activation 
of MASPs, which cleave C2 and C4, enabling the formation of C3 convertase (the converging point of all three 
complement activation pathways). The initiation of the complement cascade may also depend on other proteins. 
For example, properdin (CFP; also down-regulated at day 75) is capable of activating the alternative complement 
pathway by stabilizing the C3 convertase and by promoting its de novo assembly.
FCN1 is a lectin component of secretory granules, primarily expressed in granulocytes and monocytes. 
FCN1 may contribute to the activation of the complement system via the lectin  pathway38. Since it binds back 
to granulocytes upon release, human FCN1 plasma levels are relatively low but reflect granulocyte  counts39. In 
addition, plasma concentrations vary across time as a result of the lectin pathway activation/consumption38.
MASPs are homologs of C1r and C1s of the classical complement pathway. MASP-2 is necessary for man-
nose-binding lectin (MBL)-mediated complement activation via the lectin pathway, while the functional role of 
MASP-1 in the MBL complex is  unclear40.
MASP-1 and MASP-2 were among the most strongly downregulated proteins at day 75. These proteases 
participate in the complement activation via the lectin pathway. Indeed, both are able to cleave the coagulation 
factors prothrombin, fibrinogen, factor XIII, and thrombin-activatable fibrinolysis inhibitor in vitro41,42. Thus, 
MASPs may contribute to the formation and stabilization of cross-linked fibrin. In vitro, MASP-1 and MASP-2 
are triggered by the combined effect of platelet activation and fibrin  formation43. MBL/MASP-1/2 complex has 
thrombin-like  activity40. In line with this, mice lacking MBL or MASP-1 demonstrate a significantly prolonged 
bleeding  time40. Altogether, these results show that different key components of the coagulation cascade, as well 
as several activation pathways of the complement cascade are found at decreased levels after 75 days p.i. with A. 
vasorum in dogs. Therefore, lacking amounts of these proteins may explain (at least partially) the onset of bleed-
ing disorders; however, further targeted studies will be required in order to validate this hypothesis.
Coagulation factors V and XIII-B were detected at lower levels at day 75 compared to before infection. 
Together with fibrinogen β chain among other molecules, they are key players of fibrin clot formation. Factor V 
is the plasma cofactor for the prothrombinase complex that activates prothrombin to thrombin. It is both present 
in platelet alpha-granules and in plasma; low FV levels are seen in liver or platelet  disorders44. Overall, human 
patients with lower FV levels are more likely to have bleeding episodes than those with higher levels; the severity 
of the clinical picture is determined by the FV activity  level44. In A. vasorum infections, decreased FV activity 
has been described in both experimentally and naturally infected  animals13,14,26.
FXIII is the last zymogen to become activated in the coagulation cascades and stabilizes fibrin clots. This circu-
lating heterotetrameric pro-transglutaminase complex is composed of two catalytic FXIII-A and two protective/
regulatory FXIII-B  subunits45. The roles of FXIII-B remain incompletely resolved; it bears 10 sushi domains (or 
Complement Control Protein modules) and resembles complement factor H based on sequence and structural 
 homology46. FXIII deficiency may be acquired, as a result of immune-mediated inhibition, defective synthesis 
and/or consumption of either of FXIII  subunits47. In human blood, potential interactors of FXIII-B include 
fibrinogen-α, -β, and -γ chains, complement C1q, and C3. In addition, alpha-2-macroglobulin was suggested to 
be a direct interactor of FXIII-B45. Alpha-2-macroglobulin is a known substrate for FXIIIa, although no clear 
functional role has been discovered in this context; to date there are no reports of its direct interaction with 
FXIII-B45,48. Alpha-2-macroglobulin can inhibit both coagulation and fibrinolysis by acting on thrombin or 
 plasmin49. Hence, it was proposed that the interaction of alpha-2-macroglobulin with FXIII or FXIII-B subunit 
might fine-tune the two different  processes45. The association between FXIII-B and fibrinogen was shown several 
times; the subunit playing important roles in the formation of a stable fibrin clot. Thus, FXIII-B deficiency may 
result in increased bleeding tendency through impaired fibrin stabilization due to decreased FXIIIa activation by 
thrombin and secondary FXIII-B deficiency arising from enhanced circulatory  clearance46. FXIII’s association 
with the complement system has been described, whereby FXIII-mediated covalent cross-linking of fibrin to 
complement C3 could contribute inflammatory roles in pro-thrombotic  states50.
ADAMTS13, another downregulated protein, is a von Willebrand factor-cleaving protease showing several 
thrombospondin domains; DIC has been associated with reduced ADAMTS13  activity51. HRG interacts with 
a large panel of ligands and acts as a regulator of coagulation and fibrinolysis as both anti- and pro-fibrinolytic 
activities have been  proposed52. In septic mice, where DIC is part of the clinical picture, HRG levels were sig-
nificantly decreased. HRG supplementation antagonized the pro-DIC state, the immunothrombotic events, and 
inhibited lung  inflammation53.
Several hypotheses have been formulated underlying behind the pathogenesis of coagulopathies in A. vaso-
rum infected  dogs7. DIC and consumption coagulopathy have been the most popular explanations, sometimes 
combined with other above-mentioned  features13,14,16,26. DIC is a life-threatening condition to both humans 
and animals; it is associated with poor prognosis in dogs. It may arise as a secondary complication in numerous 
disorders and is characterized by the systemic (and excessive) activation of coagulation leading to the formation 
of microthromboses. In humans, multiple organ failure and simultaneous bleeding consequently occur due to 
consumption of platelets, clotting factors, and  fibrinogen6,7,54.
Under DIC conditions, the fibrinolytic activity is largely suppressed in experimental models. A pro-fibrino-
lytic response is almost immediately followed by a suppression of fibrinolysis due to a sustained increase in 
plasma levels of plasminogen activator inhibitor, type  154. None of these elements appeared dysregulated in our 
A. vasorum-infected dog sera.
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Substantial differences exist between controlled laboratory infections and dogs presented to the clinics: the 
number of ingested infectious larvae, the duration of the infection, and the occurrence of repeated infections are 
usually unknown in naturally infected animals. The health status, age, as well as genetic variation across breeds 
may also impact the outcome of an infection. Our study relies on serum and not on plasma; hence, lesser amounts 
of some clotting agents, i.e. fibrinogen, factor II, V, and  VIII55, are expected to be seen as a result of the induced 
clot formation. Due to the applied column-based protein enrichment, upregulation of proteins such as albumin, 
usually present at high levels in serum even at a healthy baseline level, was not expected.
Conclusion
Our data do not support the claim of classic DIC to occur. Instead, we showed that the coagulation and comple-
ment cascades are affected over the course of the infection, the lectin pathway in particular. After summarizing 
potential reasons for the onset of bleeding in A. vasorum infections, Sigrist and colleagues wrote “A differ-
ent, previously undetected pathomechanism leading to bleeding diathesis in A. vasorum infection therefore is 
expected”7. Several coagulation constituents being present at reduced levels in serum from dogs harbouring a 
patent infection, we propose a consumption of some key factors to be potentially at the origin of the onset of 
bleeding disorders. Concomitantly, upregulated components (i.e. CHI3L1 and SFTP) of the immune system 
support the important role of triggered immunological reactions contributing to the clinical picture of canine 
angiostrongylosis. Findings from this work do not provide a conclusive and mechanistic explanation for the 
coagulopathies in A. vasorum infections but provide a few leads to shape future research on the role of FXIII-B 
(for its roles in fibrin stabilization), MASP-1 and -2 (for their thrombin-like activity and as regulators of fibrin 
clot formation and stabilization), ADAMTS13 (involved in von Willebrand factor cleavage), and HRG (as a 
regulator of coagulation and fibrinolysis) in particular.
Methods
Ethics statement. Ethical clearance for the initial studies conducted in  200824,25 was obtained from the 
Cantonal Veterinary Office of Zurich (permission number 185/2008). All experiments were conducted in 
accordance with the Swiss cantonal and national regulations on animal experimentation.
Experimental design. Briefly, eight beagles (5 males and 3 females, 11 months of age at the start of the 
experiment) were inoculated with 200 A. vasorum third-stage larvae as described in previous papers based 
on the same  animals24,25. Each animal was subjected to a weekly clinical check-up with a focus on respiratory 
abnormalities, as well as faecal examination to monitor the infection through the excretion of first-stage larvae. 
There was no systematic haematological analysis. Each dog was sampled repeatedly over the course of the infec-
tion. Time points were selected in order to reflect serum profiles (i) before infection (one week prior to infec-
tion; day-7), (ii) during prepatency (day 34 post-infection (p.i.)), and (iii) after patency (day 75 p.i.; see Fig. 1a). 
Hence, each dog is represented by an uninfected (baseline) sample and at least two time points during ongoing 
infection. Serum from two further time points (days 104 and 230 p.i.) was analysed additionally. Due to require-
ments associated with animal experimentation, samples from late time points were available for two dogs only.
Serum collection and processing. Blood was collected from the jugular vein into serum tubes (Greiner 
Bio-One Vacuette Z serum clot activator (silica particles)) and spun down for 10 min at 1800 × g, prior to storage 
at − 20 °C for 9 years. Protein enrichment was performed using the ProteoMiner small capacity kit (Bio-Rad) 
following the manufacturer’s instructions. Proteins were precipitated using trichloroacetic acid (TCA) accord-
ing to a modified protocol by Thermo Fisher/Pierce. Briefly, 50 µl protein eluates were mixed with 450 µl  dH2O, 
100 µl sodium deoxycholate 0.15% (w/v), and 100 µl TCA 72% (w/v). After a 30 min incubation at 4 °C samples 
were vortexed, spun 30 min at 16,900 × g, 4 °C, and pellets were washed 3 times with pure ice-cold acetone. Pel-
lets were air-dried and resuspended in 50 µl 4% SDS, Tris–HCl 0.1 M, pH = 7.6, 0.1 M DTT. Protein in samples 
was quantified by Qubit protein assay (Thermo Fisher Scientific). Thirty µg protein were further alkylated and 
digested using a modified filter-aided sample  preparation56 (see Supplementary Methods). Dried peptides were 
resuspended in 3% acetonitrile (ACN), 0.1% formic acid (FA) and frozen at − 20 °C pending use.
Data‑independent acquisition and analysis. Samples were processed in randomized blocks, and ana-
lysed in random order. A total of 28 label-free analyses were performed in a LC–MS/MS experiment using a 
data-independent acquisition (DIA) protocol. Quality check consisted of an assessment of trends in precursor 
m/z errors, and fragment ion errors, as well as of the proportion of missed cleavage and consistency in cysteine 
modification across samples. Peptide concentration was adjusted to 0.5 µg/ml in 3% ACN, 0.1% FA, and reten-
tion time normalization peptides (iRT, Biognosys) were added at a 1:20 ratio. Three μl purified peptide mixture 
(1.5 µg on column) per sample was analysed in random order in DIA mode on a hybrid quadrupole-Orbitrap 
mass spectrometer (Q Exactive HF, Thermo Scientific) operated in line with a nano UHPLC system (Easy-nLC 
1000, Thermo Scientific). For further details see Supplementary Methods.
Spectral libraries (data-dependent acquisition mode) were produced for each time point based on pooled 
samples from each dog in equal amounts. Raw data was processed in Proteome Discoverer (v. 2.1; Thermo 
Fisher Scientific) and Spectronaut (v. 11; Biognosys), using the reference proteomes of Canis lupus familiaris 
(UP000002254), A. costaricensis and A. cantonensis (UP000050601, UP000035642) from UniProt (accessed on 
28th of August 2017). Peptide-level data was further exported from Spectronaut and analysed using the MSStats 
R package (v 3.12.3) for statistical relative quantification and significance  analysis57 and the following param-
eters: log transformation: 2; normalization method: equalizeMedians, summary method: Tukey’s median polish; 
censored values in intensity column: null; MBimpute: false. Note: The fitted model took repeated sampling from 
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the same study subject (dog) into account. Significance cut-offs for up- or downregulation were defined by an 
adjusted p-value ≤ 0.05 and fold-changes ≥ 2, or ≤ − 2. Pathway enrichment was done using STRING DB v11. 
Up- or downregulated proteins, as defined by the cutoffs set in MSstats, were submitted to the STRING online 
 tool58. Networks were produced by linking interacting proteins based on confidence in the interaction. Func-
tional protein–protein interactions were built based on the highest confidence score (≥ 0.9), computed as  in59. 
STRING pathway enrichment relies on serval databases (Biocarta, BioCyc, GO, KEGG, and Reactome). Gene 
ontology terms associated with sets of proteins were obtained using Blast2GO v 4.160. The mass spectrometry 
proteomics data have been deposited to the ProteomeXchange Consortium via the  PRIDE61 partner repository 
with the dataset identifier PXD016881. For further details see Supplementary Methods.
Confirmation of differential protein abundance by targeted mass spectrometry. Details on 
PRM assay development, characterization, and application to serum samples can be found in Supplementary 
Methods.
Data availability
The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the 
 PRIDE61 partner repository with the dataset identifier PXD016881 and PXD016887. Targeted proteomics data 
was submitted to PanoramaPublic and can be accessed using [https ://panor amawe b.org/whmPy d.url]. The R 
code (MSstats) is available upon request to the corresponding authors.
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